Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.
about
Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirusCytokine synergy: an underappreciated contributor to innate anti-viral immunityBlock of death-receptor apoptosis protects mouse cytomegalovirus from macrophages and is a determinant of virulence in immunodeficient hostsBystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clonesSpecific dysregulation of IFNγ production by natural killer cells confers susceptibility to viral infectionIdentification of key peptide-specific CD4+ T cell responses to human cytomegalovirus: implications for tracking antiviral populations.Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly.Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathwayMaintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.The human cytomegalovirus UL26 protein antagonizes NF-κB activation.Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccineIdentification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2.Novel cell type-specific antiviral mechanism of interferon gamma action in macrophagesHuman cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway.Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels.Immunobiology of human cytomegalovirus: from bench to bedside.Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines.CD4(+) lymphocyte-mediated suppression of cytomegalovirus expression in human astrocytes.Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells.Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection.Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expressionReduced expression of HLA class II molecules and Iinterleukin-10- and transforming growth factor beta1-independent suppression of T-cell proliferation in human cytomegalovirus-infected macrophage cultures.Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65Cross-presentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cellsCXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10.Murine cytomegalovirus infection inhibits tumor necrosis factor alpha responses in primary macrophages.A Diverse Repertoire of CD4 T Cells Targets the Immediate-Early 1 Protein of Human Cytomegalovirus.Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment.The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts.Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.
P2860
Q21092179-C11E89DC-0A52-47E4-A983-03AECE6DB9B6Q26852421-F801C68C-B968-4826-8871-70C490ED386FQ27339746-C4E8024C-4D91-469C-9094-3742AB8AC445Q27469356-B7BECA74-4A91-46AF-8778-809B7C9C778AQ28542517-CA1A3C49-017A-4E6F-AA6E-3B570CB425A8Q33260079-98C626C7-37C5-4595-B4EE-53C66DBFD5ADQ33716874-2FB031C8-5958-460E-9B8D-68E0049B3CDFQ33957986-A3EFABE7-35C3-4CAC-BB37-07EB9523261FQ34152994-334AE62C-9DA2-404D-A50B-996D938C98ABQ34594875-AFAA0877-D10A-44A2-92DE-6B999241CA75Q34788895-C0C980B3-C93C-4F01-B682-7557B3462307Q35156297-2EE43D8E-B9B1-46BE-8D60-AFB1C3D15D80Q36376172-BBC381FE-EC46-40E2-A57E-C73577DA0F24Q36400431-5F2E74A6-036B-4D43-9D4F-B637501F7E82Q36401507-D00D1240-06BB-4187-A79A-8C3A94A6F347Q37050965-FC57C3BD-3E53-403C-ABDE-F87C90BD7A35Q37376709-FAFCF587-1006-4BAA-9BCD-6DC7DAB29F35Q39507440-5732A407-B2D5-4519-B187-BC89FD9B1002Q39539524-3EC39FB5-FB17-48B0-AA45-26487FD83893Q39577917-EB40203D-55DB-4007-A2FD-36C381E60CECQ39595303-871380EB-F3CE-4B75-B308-5BF6E4CD2DF4Q39606146-32CF634E-953A-4B83-85C7-30A5E16E378AQ39606662-D5846B30-621E-49D1-923A-301E193E8B15Q39681740-C6282A20-DAD3-498E-ABED-C7F224574868Q39742087-D8AFC309-CF69-4CE1-ADD6-49A8D37C1578Q39996413-CE237E71-7CAE-4D05-AF25-35421A2505ECQ40883276-F9B4FA00-BF00-467B-A0EB-4FB564340859Q42125469-96530008-C769-4A58-B8A0-6E4F682A41E9Q43215263-1B02A225-2AE6-49DF-A9CD-4B5BFB22CB48Q50025140-2A02F118-BB0B-40DA-A2F8-E32595ECA06B
P2860
Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Anti-human cytomegalovirus act ...... ated by IE1 peptides in vitro.
@ast
Anti-human cytomegalovirus act ...... ated by IE1 peptides in vitro.
@en
type
label
Anti-human cytomegalovirus act ...... ated by IE1 peptides in vitro.
@ast
Anti-human cytomegalovirus act ...... ated by IE1 peptides in vitro.
@en
prefLabel
Anti-human cytomegalovirus act ...... ated by IE1 peptides in vitro.
@ast
Anti-human cytomegalovirus act ...... ated by IE1 peptides in vitro.
@en
P2093
P2860
P1433
P1476
Anti-human cytomegalovirus act ...... vated by IE1 peptides in vitro
@en
P2093
P2860
P304
P407
P577
1996-04-01T00:00:00Z